Dapoxetine, a selective serotonin reuptake inhibitor, is considered an antidepressant drug and has been developed for the treatment of premature ejaculation. Hence the objective was to assess whether dapoxetine administration to male rats adversely affect sexual behavior and pregnancy outcomes after mating with untreated female rats. Proven fertile male rats were gavaged with 0, 2.0, 4.0 and 8.0 mg dapoxetine per kg body weight (bw) per day (DC, DI, DII and DIII groups, respectively) for 70 days prior to mating with untreated female rats. Weight gain, organ weights and feed consumption were decreased significantly in the DII and DIII groups. A significant decline in the number of spermatozoa in the DII and DIII groups is attributed to a significant decrease in testosterone, luteinizing hormone and follicle-stimulating hormone. Levels of prolactin were significantly increased in the DII and DIII groups. Rats treated with a high dose of dapoxetine (8.0 mg kg − 1 ) showed a significant inhibition in sperm motility and increment in sperm abnormalities. There was a pronounced decrease in fertility index in females mated with males treated chronically with 4.0 and 8.0 mg per kg bw dapoxetine. In addition, the treatment markedly increased the number of fetal resorptions in female rats impregnated by males in the DII and DIII groups reflecting their infertility. The number of implantation sites and the number of viable fetuses were also notably decreased in female rats impregnated by males given 4.0 or 8.0 mg kg − 1 dapoxetine. These findings suggest that the long-term dapoxetine at high dosages causes failure of the fertilization or successful impregnation of the females mated with dapoxetine-treated male rats, which were clearly able to copulate. A detrimental effect of dapoxetine on fertility parameters was also revealed. -9930/15 www.nature.com/ijir N = 10 rats; mean ± s.d. Data obtained were assessed by analysis of variance and post-hoc Mann-Whitney U-test. a P ⩽ 0.05 vs the control group. b P ⩽ 0.05 vs the DII group. c P ⩽ 0.05 vs the DI group.
INTRODUCTION
For the past decade, selective serotonin reuptake inhibitors (SSRIs) have been used in the psychotherapy to premature ejaculation (PE) treatment paradigm. 1 Well-established evidences from the studies have demonstrated the efficacy and safety of SSRIs in lateness of ejaculation, confirming their role for the treatment of lifelong and acquired PE. 2, 3 Among common SSRIs, a new serotonin transporter inhibitor, dapoxetine, has been developed specifically for the treatment of PE. 4 Although it is not prescribed for the treatment of PE, conventional SSRI antidepressants are commonly used to treat the condition. 5 The pharmacokinetic profile of dapoxetine suggests that it is a good candidate for ondemand treatment of PE. 6 Dapoxetine was effective when taken on-demand, 1-3 h before intercourse. In spite of the growing use of prescription SSRIs on PE and depression (emission and ejaculation), 7 only clinical reports have evaluated the effect of SSRIs on male fertility or sperm quality. 8 Tanrikut and Schlegel 9 showed two clinical cases with oligoasthenospermia who were prescribed citalopram and sertraline. Further, studies demonstrated a relationship between use of SSRIs and decreased sperm motility. 10 In addition, chronic SSRI treatment can affect spermatogenesis, impair sperm transport, damage the sperm cell membrane and alter sperm DNA. [11] [12] [13] [14] Likewise, in vitro evidence reveals that SSRIs have a spermicidal effect. 15 In the literature, no attention has been paid to the reproductive consequences of dapoxetine treatment on the basis of animal and human studies. Also, no information is available related to the effects of dapoxetine on fertility, sperm measures and pregnancy outcomes or embryo/fetal development. All dapoxetine drug treatment reports and studies were conducted for pathophysiology of PE.
According to the point of view that treatment of PE and depression with conventional daily dosing of dapoxetine is the high incidence of sexual side-effects. Therefore, the present study was planned to evaluate the reproductive toxicity and its adverse effects on fertility parameters in usual prescribed doses.
MATERIALS AND METHODS Dapoxetine treatment and rat groups
Healthy male Wistar rats, 150-155 g body weight (bw) (approximately 3 months old), were housed five per polyprophylene cage and acclimatized to an animal house of Zoology Department, Faculty of Science, Alexandria University with controlled laboratory conditions (25 ± 2°C, 50-60% humidity and 12-h light/dark) and provided with laboratory chew and water ad libitum. The males were randomly divided into three experimental (DI, DII, DIII) and one control group (DC) of 20 rats each. The experimental groups were daily gavaged dapoxetine hydrochloride (Inspire Pharmaceutical Company, IPC Pharma, Cairo, Egypt) at 1 doses of 2.0, 4.0 or 8.0 mg kg bw − 1 in 0.5 ml saline and the controls with 0.5 ml saline for 70 days. Alexandria University's Institutional Animal Care and Use Committee (IACUC) is responsible for approving and reviewing all ethics protocols involving live vertebrate animals, ensuring compliance with regulations, inspecting animal facilities and laboratories and overseeing training and educational programs. The overall role of the IACUC is to ensure the humane and sensitive care and use of animals. Regulations of guidelines for the study of repeated oral dose toxicity in rodents provided by the Organization for Economic Cooperation and Development (OECD) 16 was followed for the treatment of animals throughout the present study.
Clinical toxicity and adverse effects of dapoxetine
The clinical examinations for toxicity were conducted according to the World Health Organization guidelines. 17 All animals were observed daily for 70-day period and mortality was monitored, if any. Simultaneously, side-cage observations were made for changes in skin, fur, eyes and mucous membrane, incidence of secretions or excretions external, texture changes, mobility, aggression and other gross behavioral changes, if any. Other activities such as lacrimation, piloerection, pupil size, tremor, convulsion, salivation, diarrhoea, lethargy, sleep, respiration pattern, changes in gait, posture and response to handlings, if any of it appeared was also monitored and recorded daily.
Feed consumption and body weights
Total feed consumed was recorded daily and calculated in percentage using the formula of Vento et al. 18 Body weight of each rat was recorded at the starting of the treatment as initial weight and at the end of the treatment just before necropsy as final body weight using digital weighing scale (Tanita KD-200, ScalesGalore.com, USA). 19 
Organ weights
After 24 h of the last dosing of the stipulated day of experiment, 10 rats of each group were sampled. Complete macroscopic examinations were performed on all animals. Rats were killed by an overdose of diethyl ether, dissection was performed and weights of the brain, testes and epididymides were accurately estimated for the dapoxetine-treated and control groups.
Sera and hormonal assays
Sera were separated by centrifugation (3000 g, 15 min) from the blood collected via the dorsal aorta and stored at − 20°C until biochemical assays. In rat serum, the luteinizing hormone (LH) and folliclestimulating hormone (FSH) levels were determined quantitatively by the radioimmunoassay method 20 using commercially available kits from Bio-diagnostic group's Laboratories (Giza, Egypt). For the determination of testosterone and prolactin (PRL), the methods of Wheeler 21 and Smith and Norman 22 were used, respectively. Samples were run in the same assay to avoid inter-assay variations.
Sera and biochemical markers
The serum was used for the assay of biochemical markers and cholesterol 23 concentrations by enzymatic colorimetric determination using commercial laboratory kits.
Sperm prognosis
Sperm suspension. The content of the epididymis was squeezed into 1 ml of prewarmed phosphate-buffered saline (pH7.2, 37°C) for 20 min. The spermatozoas were allowed to disperse into the buffer. The suspension was gently shaken to homogenize and filtered through a double layer of muslin cloth. 24 The other testes and epididymes were frozen in − 20°C until usage.
Sperm count and morphology. For sperm counting, the filtrated sperm suspension was stained with 1% aqueous eosin Y (10:1) and left for 30 min. Approximately 10 μl of the stained epididymal sperm suspension was transferred into a Neubauer hemocytometer (Hausser Scientific Company, Horsham, PA, USA) and let to stand for 7 min. 25 For sperm abnormalities, a drop of stained sperm suspension was smeared on glass slides and observed under a microscope (Olympus, CX23, Japan) (1000 spermatozoa per animal). 26 To minimize the error, the count was repeated three times on each sample. 27 Sperm motility. To assess the percentage of sperm motility, small aliquot (10 μl) of freshly prepared sperm suspension with a micropipette was smeared on a warmed slide glass at 37°C. Motility was assessed by counting all effective spermatozoa that move in direct pathway, indefinite pathway or no immobility in the same microscopic field. In each semen slide, random 10 fields were examined, with at least 100 sperm/field counted. The number of motile sperm per field was divided by the total number, and the average of the fields was assayed. The percentage of motile spermatozoa was determined. 28 Sperm viability. Sperm viability was assessed using the eosin Y-nigrosin stain. Ten microliters of the freshly collected sperm suspension were placed on a glass slide and mixed with 10 μl stain. 29 Under the microscope at × 400, live spermatozoa appeared unstained, whereas those that showed any pink or red stain were classified as dead. Randomly, at least 200 sperm were examined from each sample in 10 fields, and the percentage of live sperms was recorded. 30 Viability was evaluated according to World Health Organization guidelines. 27 Daily sperm production and sperm transit From the previously collected testes and epididymdes (right and left), sperm content per gram was estimated with some modifications on the method described by Faqi et al. 31 In general, the testis and cauda epididymes was cleaned from adhering connective tissue and tunica albuginea and weighed. Each testis and cauda epididymis was minced and homogenized separately for 5 min in 10 ml of 0.9% NaCl containing 0.5% (v/v) Triton X-100 followed by filtration through a nylon mesh. The homogenates were diluted with 1.5 ml of Hank's Balanced Salt Solution. The suspension was then used for the estimation of homogenizationresistant elongated spermatid (stages [17] [18] [19] and spermatozoa by light microscopy using Neubauer hemocytometer chamber. Three counts per testis/epidydimis were averaged. These count values were used to obtain total number of spermatids per testis and sperm per epididymis; this was then divided by the testis/epididymis weight to determine the number per gram of testis/epididymis. 32 Daily sperm production by the rat testes is measured by counting the number of condensed spermatids in a testes homogenate, expressed as the number per testis or per gram of testis. 33 Then the number of spermatozoa per testis can be divided by 6.1 days (the period that spermatids reside in the testis after their chromatin condenses and they become resistant to disruption by homogenization or sonication). Sperm transit time through the epididymal caput/corpus and cauda was obtained by dividing the number of spermatozoa present in each of these regions by daily sperm production. 34 
Sperm DNA integrity
To test sperm DNA integrity, thin dried smears prepared from the sperm solution were stained with acridine orange according to a protocol described by Tejada et al. 35 In brief, the smears were fixed for 14 h in methanol/acetic acid (3:1) at 4°C and stained with acridine orange solution (0.19% in phosphate citrate buffer, pH = 2.5) for 10 min. The slides were gently washed by distilled water for 5 min and air dried. The stained smears were then examined with the aid of fluorescent microscope (460 nm filter) at × 1000 magnification. Green spermatozoa were considered with normal double-stranded DNA content, whereas yelloworange to red sperms were considered with single-stranded DNA (damaged DNA). At least 100 spermatozoa per slide were counted to evaluate the percentage of double-stranded DNA in the spermatozoa.
Male reproductive end points
Copulation and fertility index. The remainder 10 treated and control counterparts male rats were assessed for the copulatory ability after 70 days of dapoxetine dosing by applying the method of Manson and Kang. 36 One day after treatment termination, each male rat was co-housed in a separate cage with two unexposed proven fertility females in natural estrous (sexually receptive) of the same strain. They were left together for at most 5 days (period of one regular estrous cycle) 37 following which they were separated. The females were examined daily for the presence of the vaginal plug as a criterion of successful insemination that was considered the day 0 of gestation. 38 To estimate the fertility potency, each plugpositive female was caged individually. The most indicative fertility end points were recorded. Copulation index and fertility index, in addition to the conception time, the interval between the first day of cohabitation and the day of vaginal plug and/or sperm in the vaginal fluid, were recorded for each female.
Pregnancy outcomes. The pregnant females were anesthetized with diethyl ether and killed at twentieth day of gestation. After collection of the gravid uteri and ovaries, the numbers of corpora lutea, implantation sites, resorptions, live fetuses and fetal weights were determined. From these results, the following were determined: fertility potential (efficiency of implantation): implantation sites/corpora lutea × 100; preimplantation loss and postimplantation loss, and sex ratio. Uteri that appeared nongravid were stained with ammonium sulfide 39 to confirm pregnancy status and examined for evidence of implantation sites. And then pregnancy indices were calculated according to the method of Adilaxmamma et al. 40 Dapoxetine and sexual behavior After 70 consecutive days of daily dapoxetine treatment, randomly selected 10 male rats from the control and treated group were individually tested for sexual behavior in a rectangular glass observatory cage and allowed 10-min for accommodation period. The copulatory behavior was undertaken between 0800 and 2300 hours in illumination by low-level of red light. Thereafter, an estrous female (sequential subcutaneous injections of estradiol benzoate (10 μg per 100 g) and progesterone (0.5 mg per 100 g), 48 and 4 h, respectively, prior to pairing) 41 was introduced into the cage. Estrous phase in female rats was confirmed by vaginal smear examinations according to OECD 42 guidelines. Then the masculine sexual behavior was monitored along 30 min after pairing. 43, 44 The following measures were recorded: mount and intromission latencies, defined as the times from introduction of the female in the cage to the first mount and intromission, respectively; intromission frequency, the number of intromissions preceding the first ejaculation; ejaculation latency, the time from introduction of the female into the cage to the first ejaculation; intromission latency postejaculation, the time to the first intromission after the first ejaculation; and intromission frequency postejaculation, the number of intromissions after the first ejaculation; total number of ejaculations. 45 If the male did not mount in the next 10 min after the introduction of one adult female in the box, it was considered sexually inactive.
Statistical analysis
The results were expressed as mean ± s.d. Statistical analysis was carried out using the Statistical Package for Social Sciences (version 16; SPSS, Chicago, IL, USA) software. The significance of the differences between the groups was assessed by one-way analysis of variance and post-hoc Mann-Whitney U-test. Probability levels were considered statistically significant at Po0.05.
RESULTS

Toxicological signs and mortality
Autonomic functions and central nervous system toxicity were most prominent postdosing signs in males dosed 4.0 and 8.0 mg kg bw − 1 day − 1 (DII, DIII). These included mydriasis, soft stool, lacrimation, tremors, hypoactivity, recumbent posture, ataxia and vomiting compared with the control (DC) and low-dose groups (DI). These symptoms noticed immediately after 2 and 1 h of 60% and 80% of treated males administered 4.0 and 8.0 mg kg bw − 1 day − 1 (DII, DIII) dapoxetine, respectively, and progressed to a lesser extent in the same animals throughout the second half of day period. Lethargy (in each group) was also observed in the two higher-dose groups of rats treated orally with dapoxetine (4.0 and 8.0 mg kg bw − 1 day − 1 ; DII, DIII).
Body weight and organ's weight
At the end of the treatment, male body weight gain was significantly decreased in the treated group of 4.0 and 8.0 mg kg bw − 1 day − 1 (DII, DIII) (P o0.05) compared with the control (DC) and the other treated group (DI) ( Table 1) . No statistically significant differences in relative brain or epididymides weights were noted in any of dapoxetine-treated groups compared with the control group (DC). However, relative testes weights were reduced dramatically in male treated with 4.0 and 8.0 mg kg bw − 1 day − 1 (DII, DIII) dapoxetine compared with the 2.0 mg kg bw − 1 day − 1 treated group (DI) and control (DC) ( Table 1) . Screening of body weight provides an index of general health status of the male rats, which in turn leads to the interpretation of reproductive health.
Food intake Food consumption was significantly (P o 0.01) decreased in the treated groups of 4.0 and 8.0 mg kg bw − 1 day − 1 (DII, DIII). No statistically significant differences were observed in food consumption between the vehicle control (DC) and 2.0 mg kg bw − 1 day − 1 (DI) groups (Figure 1 ).
Total cholesterol
There was a significant decrease in total cholesterol values after treatment with high doses of dapoxetine (4.0 and 8.0 mg kg bw − 1 day − 1 , DII, DIII) compared with control (DC) and 2.0 mg kg bw − 1 day − 1 (DI) values ( Figure 2 ).
Reproductive hormones levels
Chronic dapoxetine treatment significantly (Po 0.01) decreased the serum LH and FSH concentrations in 4.0 and 8.0 mg kg bw − 1 day − 1 (DII, DIII) doses (Figure 3 ). Serum testosterone was also the lowest in these groups, this was statistically significant (P o 0.05; Table 2 ). Moreover, the administration of dapoxetine revealed elevation in the PRL hormone concentrations in rats treated with 4.0 and 8.0 mg kg bw − 1 day − 1 dose (Table 2) . Table 3 ). There was a marked reduction (Po0.01) in normal formed sperm in the 4.0 and 8.0 mg kg bw − 1 day − 1 treated groups (DII, DIII) as a result of a high teratozoospermia (P o0.05). The lower dose (2.0 mg kg bw − 1 day − 1 , DI) did not cause any significant alterations in the sperm motility on seventieth day after oral treatment compared with the control group (DC). However, a statistically significant inhibition in the sperm motility was noticed in the male rats, which received 4.0 and 8.0 mg kg bw − 1 day − 1 of dapoxetine (DII, DIII; Table 3 ). There was a dosedependent increase in the number of dead spermatozoa where the high toxicity observed in the 8.0 mg kg bw − 1 day − 1 group (DIII). Although the daily sperm production reduced in the 8.0 mg kg bw − 1 day − 1 group (DIII) (Figure 4 , P o0.05), the sperm transit rate was not altered by the 70-day treatment of animals with dapoxetine (DI, DII, DIII) when compared with control animals (DC) ( Figure 5 ).
Sperm viability
The percentage of viable sperms was a significantly decreased (P o 0.001) in 4.0 and 8.0 mg kg bw − 1 day − 1 compared with the 2.0 mg kg bw − 1 day − 1 and control groups ( Table 3 ).
Sperm DNA integrity By acridine orange, spermatozoa showed that 2.0 mg kg bw − 1 day − 1 dapoxetine had no significant damage on the sperm DNA integrity compared with the control (Figure 6 ). However, acridine orange staining revealed a significant evidence of DNA damage in 4.0 and 8.0 mg kg bw − 1 day − 1 (DII, DIII) dapoxetine-treated male rats compared with the control (DC) ( Figure 6 ).
Effects of dapoxetine on male fertility and reproductive performance
Fertility and reproductive performance of male rats treated with dapoxetine is shown in Table 4 . Although male copulation index was decreased only in the 8.0 mg kg bw − 1 day − 1 group (DIII); fecundity index was significantly decreased in both the 4.0 and 8.0 mg kg bw − 1 day − 1 groups (DII, DIII) compared with the control value (DC). There were statistical significant differences in the number of implantation sites and live fetuses in the 8.0 mg kg bw − 1 day − 1 treated group (DIII) compared with the control group (DC), although no significant differences were observed in the number of dead fetuses in any of the experimental groups. However, there were statistically significant increases in the number of late and early resorptions (total resorption) in the 8.0 mg kg bw − 1 day − 1 group (Figure 7) . Also, an increase in percentage of preimplantation and postimplantation loss in untreated females mated with rats administered with 4.0 and 8.0 mg kg bw − 1 day − 1 dapoxetine for 70 days, indicating decreased fertility efficiency. In addition, mean fetal weights and litter sizes were, however, decreased in comparison to litters sired from control males (Figure 7 ). 
Sexual behavior end points
In the present observations, the precopulatory behavior and signs of sexual vigor such as anogenital sniffing and licking and chasing the female were less manifested with the 4.0 and 8.0 mg kg bw − 1 day − 1 dapoxetine groups as soon as the female was introduced. So, these treated males took onefold to threefolds more conception time to impregnate females, respectively (Table 5 ). However, insignificant differences of sexual behavior parameters between control and low-dosage treated groups were observed. At day 70, dapoxetine had significant effect (P o 0.001) in a dose-dependent manner on all parameters investigated when compared with the control. In the 4.0 and 8.0 mg kg bw − 1 day − 1 dosed group, mount frequency (MF), intromission frequency (IF) and ejaculation frequency (EF) decreased, whereas mount latency (ML), intromission latency (IL) and ejaculation latency (EL) increased to their respective low and control values (P o0.001).
There was also statistically significant prolongation of postejaculatory interval (P o 0.05; Table 5 ). In addition, the index of libido was significantly (P o0.001) suppressed in the 4.0 and 8.0 mg kg bw − 1 day − 1 treated males compared with the low-dosed and untreated control males.
DISCUSSION
The ataxia, hypoactivity, salivation, tremors, vomiting, diarrhea and weakness showed by male rats in the 4.0 and 8.0 mg kg bw − 1 day − 1 dapoxetine treatment groups appears to be the typical principal mode of action of SSRIs. 46 The loss of body weight and weight gain could be related to the sedative effects observed in rats 47 and subsequent reduced frequency of food intake. 48 The highly specific actions of SSRIs of enhancing serotonergic neurotransmission in the gastrointestinal tract and also probably in the central nervous system may explain the overall incidence of loss of weight and food intake, 49 which is an effect apparently mediated by impact on the serotonin (5-HT) signaling pathways. 50 Moreover, an alteration in metabolic rate may be responsible for the less weight gain. 51 It has been reported that a change in relative or absolute weight of an organ is an indication of the toxic effects. 52 SSRIs are substantially compounds identified for their ability to induce inhibition of neuronal synaptic re-uptake of serotonin, resulting in elevation of concentration of the serotonin and subsequent potentiation of presynaptic and postsynaptic serotonergic receptors. 53 On the other hand, as SSRIs, dapoxetine has specific direct inhibitory action on the regional serotonergic Effect of dapoxetine on reproductive parameters neurotransmitter system in the hypothalamus region. 54 The mechanisms of SSRI-induced sexual dysfunction are largely inferential and depends on several neurotransmitters, such as 5-HT, noradrenaline, dopamine and nitric oxide. 55 Therefore, the adverse male-mediated reproductive effects of dapoxetine may serve as sensitive end points for reproductive disruption. Dapoxetine and its metabolites are known to be potential endocrine disruptors. 56 In addition, elevation of the cerebral level of serotonin concentration cause decrease in human chorionic gonadotropin level. 57 Serotonin induces suppression of hypothalamus-pituitary-testis axis mediated by activated hypothalamuspituitary-adrenocortical axis resulting in fall of plasma LH, FSH and testosterone levels. 11 Therefore, low serum LH, FSH and testosterone seem to be the possible mechanisms of dapoxetine. 58 Another reason for decreasing a gonadotropin-releasing hormone release could be explained by increase in serotonergic and opiodergic efficacy that stimulate PRL release by suppressing the hypothalamic dopaminergic system. 59 In addition, the stimulatory effects of the dapoxetine on PRL release 60 along with hyperprolactinemic states were associated with low LH and FSH levels. 61 The increments of serotonin are consistent with the reported findings which indicated that acute doses of SSRIs in experimental animals caused alterations in concentrations of other neurotransmitters implying serotonin. 62 In the present findings, the reduced levels of testosterone could be due to the deficits of neuroendocrine cells of hypothalamicpituitary axis to respond to the loop-feedback when testosterone level decreased. 63 This reflects that serotonin do not have a pivotal impact on the interaction between the nervous and endocrine system. Furthermore, the decrease in testosterone secretion may simply represent the direct neural pathway between the hypothalamus and the testes via the participation of noradrenergic and serotoninergic neurotransmission. 64 Reduced levels of testosterone can also occur as a result of increased levels of PRL, an adverse effect and a possible negative feedback relationship between plasma testosterone and pituitary dopaminergic activity. 65 The impaired Leydig cell function is displayed by a decrease in testosterone production as a consequence of reduced expression of several important steroidogenic factors, including StAR, CYP17A1, CYP11A1 and 3β-HSD. All these factors being important components of the steroidogenic machinery may serve as susceptible targets of endocrinedisrupter actions resulting in infertility. 66 Considering the significant detrimental effects by dapoxetine on semen parameters (count, motility and morphology) could be attributed to binding capability of SSRIs to sulfhydryl groups of sperm membrane, 67 suggesting a spermicidal action of dapoxetine, 68 probably related to their interaction with both spermatozoa and inner mitochondria membranes. 69 In addition to morphology and sperm motility, the sperm DNA integrity is also deteriorated by dapoxetine. Indeed, unlike the study by Tanrikut and Schlegel, 9 the present study showed that the sperm transit did not get affected. The authors suggest that SSRIs may affect sperm transport, rather than sperm production or may damage normal sperm DNA integrity affecting fertility. 70 So the membrane damage and DNA alterations may reduce sperm count, motility and normal morphology, 71 which suggested that neuroendocrine factors have a central role in SSRIs' effects on spermatozoa. 58 Moreover, the crucial PRL/dopamine balance is crucial for normal spermatogenesis in male 72 in many species. Therefore, it is likely that the resultant local imbalance between PRL and dopamine may be responsible for some of the reproductive disorders induced by dapoxetine. Consequently, deteriorated sperm analysis following dapoxetine treatment in the present study might be due to interference of dapoxetine with differentiation of spermatozoa along with the impairment in hormonal regulation of spermatogenic process caused by the endocrine-disrupting action of dapoxetine on the testes.
The findings of the present study demonstrate that chronic dapoxetine exposure to male rats evidently influences fertility parameters in mating with normal untreated females. There was a pronounced increase in resorptions, the number of live fetuses resulting from mating was significantly less than in controls and also few implantation sites. Taken together, these observations indicate that the chronic dapoxetine regimen given in this study (4.0 and 8.0 mg kg bw − 1 day − 1 ) did not influence vaginal penetration by male rats, but markedly impact successful conception. The increased numbers of resorptions in untreated female rats mated with males treated chronically with dapoxetine indicate that vaginal penetration occurred. Thus the males were apparently able to copulate successfully and impregnate the females as indicated by the incidence of pregnancies. Furthermore, the lower number of implantation sites suggests a primary defect in the ability of sperm to fertilize eggs as indicated by significant increase in preimplantation fetal loss. There was also significant difference in postimplantation loss evident by increment in the number of resorption sites in females mated with dapoxetine-exposed males. These observations reflect that if copulation, fertilization and implantation occurred, there was little subsequent effect of paternal dapoxetine administration on fetal outcome through sperm aberrations. As motility and sperm counts were affected by dapoxetine treatment, and as was also sperm morphology, it appears that gross aberrations in sperm quality can explain the male reproductive potency and pregnancy outcomes in females mated with dapoxetine-treated males. Interestingly, formation of successful copulatory plugs by dapoxetine-treated male rats at the cervical end of the vagina was observed, indicating that ejaculation occurred with evidence of vaginal penetration. Functional interpretation of these results is that dapoxetine has no effects on the secretions of the secondary sex organs, which have an important role in fertilization and formation of vaginal plug (seminal vesicle, prostate and coagulating glands). 73 Collectively, these data suggest that the major effect of paternal dapoxetine administration is on fertility and/or implantation processes that lead to unfortunate poor pregnancy outcome in drug-naive females. 
Effect of dapoxetine on reproductive parameters
The copulatory behavior is regulated by multiple neurotransmitter systems at both the spinal and supraspinal levels, and the serotonergic system is a major mediator. 74 There is convincing evidence that increased serotonin impaired male sexual behavior and prolonged the ejaculation latency, 75 whereas noradrenergic and dopaminergic systems facilitate and increase parameters of copulatory activity. 76 Moreover, elevation of PRL levels also inhibits testosterone content, which seems to result in lowering of sexual functions. 77 Therefore, the sexual dysfunction induced by dapoxetine may be due to agonist/antagonist of dopaminergic and serotonergic mechanisms. Additionally, dapoxetine is an SSRI that inhibits nitric oxide synthase activity, which reduces the number of ejaculations. 78 The loss of libido (inhibition in MF, IF and EF) by dapoxetine may be due to reduction of mesolimbic dopaminergic activity as a result of inhibitory serotonergic midbrain raphe nuclei projections or inactivatory role of 5-HT1A receptor-mediated norepinephrine neurotransmission. 79 Taken together, these data seem to indicate that the decreases in MF, IF and EF as well as the prolonged ML, IL, EL and PEI confirm that the male rats have been sexually impaired. 80 The present data apparently display inputs that may be beneficial for human health. Dapoxetine is obviously an appropriate treatment option for PE, and its use can result in good quality of life for the patients and their sexual partners. But we need checks on the consumption of the multiple doses of dapoxetine as the chronic dapoxetine treatment has a detrimental effect on spermatogenesis, impairs sperms and/or effects hormonal balance, leading to abnormal pregnancy outcomes.
